版本:
中国

BRIEF-Epizyme reports positive interim data from Phase 2 trial for tazemetostat

June 14 Epizyme Inc

* Epizyme reports positive interim data from Phase 2 trial for tazemetostat in relapsed or refractory follicular lymphoma and dlbcl patients

* Epizyme - interim data as of June 1, 2017 show that tazemetostat treatment resulted in a clinically meaningful benefit in patients with fl

* Tazemetostat continues to demonstrate a favorable safety profile across all patient populations in this study

* As size of mutation study groups increase and patients remain on study, epizyme expects data will continue to evolve Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐